Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of IMM0306 in Participants With IgG4-Related Disease (IgG4-RD)

NCT07621939 is registered in ClinicalTrials.gov with ImmuneOnco Biopharmaceuticals (Shanghai) Inc. as lead sponsor.

NCT NCT07621939
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07621939 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II/III Clinical Study to Evaluate the Efficacy and Safety of IMM0306 in Participants With IgG4-Related Disease (IgG4-RD)
Lead sponsor
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Phase
Phase 2/3
Overall status
Not yet recruiting
Start date
July 31, 2026
Completion date
May 31, 2030
Enrollment
125 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

igg4-related disease